oxidopamine has been researched along with Basal Ganglia Diseases in 7 studies
Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).
Basal Ganglia Diseases: Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The frequency of the induction of parkinsonism-like signs was minimal in the first 2 weeks and reached a maximum point 4 weeks after the 6-OHDA injection." | 1.32 | "Hydrocephalus-parkinsonism complex": progressive hydrocephalus as a factor affecting extrapyramidal tract disorder-an experimental study. ( Hidaka, M; Kim, DS; Oi, S, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (42.86) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Oi, S | 1 |
| Kim, DS | 1 |
| Hidaka, M | 1 |
| Muñoz, AM | 1 |
| Rey, P | 1 |
| Parga, J | 1 |
| Guerra, MJ | 1 |
| Labandeira-Garcia, JL | 1 |
| Shimoyama, M | 1 |
| Kito, S | 1 |
| Itoga, E | 1 |
| Kishida, T | 1 |
| Nanba, K | 1 |
| Bourson, A | 1 |
| Boess, FG | 1 |
| Bös, M | 1 |
| Sleight, AJ | 1 |
| Carlson, JD | 1 |
| Pearlstein, RD | 1 |
| Buchholz, J | 1 |
| Iacono, RP | 1 |
| Maeda, G | 1 |
| Strömberg, I | 1 |
| Johnson, S | 1 |
| Hoffer, B | 1 |
| Olson, L | 1 |
| Brundin, P | 1 |
| Isacson, O | 1 |
| Gage, FH | 1 |
| Prochiantz, A | 1 |
| Björklund, A | 1 |
7 other studies available for oxidopamine and Basal Ganglia Diseases
| Article | Year |
|---|---|
"Hydrocephalus-parkinsonism complex": progressive hydrocephalus as a factor affecting extrapyramidal tract disorder-an experimental study.
Topics: Animals; Antiparkinson Agents; Apomorphine; Basal Ganglia Diseases; Behavior, Animal; Disease Models | 2004 |
Glial overexpression of heme oxygenase-1: a histochemical marker for early stages of striatal damage.
Topics: 5,7-Dihydroxytryptamine; Afferent Pathways; Animals; Astrocytes; Basal Ganglia Diseases; Biomarkers; | 2005 |
Binding experiments of muscarinic acetylcholine and dopamine receptors in human brains with emphasis on a case of striatonigral degeneration.
Topics: Animals; Basal Ganglia Diseases; Brain; Caudate Nucleus; Corpus Striatum; Humans; Hydroxydopamines; | 1982 |
Involvement of 5-HT6 receptors in nigro-striatal function in rodents.
Topics: Adrenergic Agents; Animals; Basal Ganglia Diseases; Benzazepines; Catalepsy; Clozapine; Corpus Stria | 1998 |
Regional metabolic changes in the pedunculopontine nucleus of unilateral 6-hydroxydopamine Parkinson's model rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antimetabolites; Basal Ganglia Diseases; Cerebral Cortex; D | 1999 |
Reinnervation of dopamine-denervated striatum by substantia nigra transplants: immunohistochemical and electrophysiological correlates.
Topics: Animals; Basal Ganglia Diseases; Corpus Striatum; Electrophysiology; Female; Hydroxydopamines; Oxido | 1985 |
The rotating 6-hydroxydopamine-lesioned mouse as a model for assessing functional effects of neuronal grafting.
Topics: Amphetamine; Animals; Basal Ganglia Diseases; Corpus Striatum; Disease Models, Animal; Dopamine; Hyd | 1986 |